Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.DCOY · Entity 937 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,001 |
Reported balance
After 2026-08-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 2,000 · Balance 2,001 F1: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. F2: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
F2: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 21:42 UTC | Decoy Therapeutics Inc. DCOY · Entity 937 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001457289-26-000003 · ownership.xml · nonDerivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,001 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:16 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000007 · wk-form4_1708636513.xml · derivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-02-19 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:03 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000010 · wf-form4_167295975197703.xml · nonDerivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,718 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024 Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 16:05 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001615219-22-000005 · wf-form4_164279908733608.xml · derivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-19 Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:55 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001615219-20-000115 · wf-form4_160711890918329.xml · derivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-12-01 Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 18:01 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001615219-20-000024 · wf-form4_158517370098647.xml · derivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2030-03-22 F1 · derivative.exercise_date: Options granted are fully vested on March 23, 2021. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 21:59 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001615219-19-000034 · wf-form4_156833993937396.xml · derivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2029-09-10 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.